Autres langues Daiichi Sankyo Company, Limited

Actions

4568

JP3475350009

Produits pharmaceutiques

Marché Fermé - Japan Exchange Autres places de cotation 08:30:00 15/07/2026			Varia. 5j.	Varia. 1 janv.
2 677,00 ^JPY	-0,09%		-1,47%	-20,04%

08/07	Les bourses européennes clôturent en forte baisse mercredi ; les prix du pétrole s'envolent avec la reprise du conflit entre les États-Unis et l'Iran	MT
08/07	AstraZeneca et Daiichi proches d'un accord sur le prix de l'Enhertu au Royaume-Uni - Bloomberg	AN

Autres langues

08/07	European Stocks Close Sharply Lower in Wednesday Trading; Oil Prices Spike as US-Iran War Reignites
08/07	AstraZeneca and Daiichi near UK Enhertu price deal - Bloomberg
08/07	UK Regulator in Talks with AstraZeneca, Daiichi Sankyo for Enhertu Pricing
08/07	AstraZeneca, Daiichi Sankyo Near Deal With UK Regulator Over Enhertu Pricing
08/07	AstraZeneca, Daiichi near UK pricing deal for breast cancer drug, Bloomberg News reports
30/06	AstraZeneca - Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours
30/06	Trump's push for the world's lowest drug prices hits snag with mid-sized companies
30/06	Daiichi Sankyo Board Approves Treasury Share Disposal Under Medium-Term Share Compensation Plan
29/06	Daiichi Sankyo - Enhertu Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
29/06	Datroway Recommended for Approval in EU for TNBC
29/06	Daiichi Sankyo and AstraZeneca Receive Approval for Enhertu as First Tumor Agnostic HER2 Directed Therapy in the EU
29/06	AstraZeneca's Enhertu Gets EU Approval for HER2-Positive Solid Tumors
29/06	AstraZeneca's Enhertu wins first EU tumour-agnostic approval for HER2
29/06	AstraZeneca, Daiichi Sankyo Win EU Approval for Enhertu in HER2-positive Solid Tumors
29/06	BT, Verizon merge international arms in joint venture
29/06	Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
26/06	European Equities Lower in Friday Trading; Unilever Weighs Offer for Thorne Valued at Up to $4 Billion
26/06	Daiichi Sankyo and AstraZeneca Announce Datroway Recommends for Approval in EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
26/06	AstraZeneca's Datroway Breast Cancer Treatment Gets Recommendation for EU Approval
26/06	AstraZeneca's, Daiichi's Datroway recommended for further EU approval
26/06	AstraZeneca-Daiichi's Breast Cancer Therapy Datroway Recommended for EU Approval
26/06	Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
24/06	Health Care Up on Rotation Into Beaten-Down Sectors -- Health Care Roundup
24/06	Daiichi Sankyo Europe Pfaffenhofen Plant (Germany) has obtained ISO45001:2018 certification
22/06	Daiichi Sankyo Approves 214 Million Yen Treasury Stock Disposal